Educational Impact of A Clinical Advances Curriculum On EGFR Exon 20 Insertion Mutated NSCLC And EGFR TKI-Resistant NSCLC

被引：0
|
作者：
Dorkhom, N. V. [1 ]
Cannon, M. [2 ]
Cohen, J. [3 ]
机构：
[1] Medscape, Naarden, Netherlands
[2] Medscape, Paris, France
[3] Medscape, New York, NY USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Continuing Medical Education; EGFR exon 20 insertion mutations; EGFR TKI resistance;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-13
引用
收藏
页码：S645 / S645
页数：1
相关论文
共 50 条
  • [21] Paraneoplastic Hypomyopathic Dermatomyositis Associated With EGFR Exon-20 Insertion NSCLC
    Zhong, Connie S.
    Russell-Goldman, Eleanor
    Murphy, George F.
    Nambudiri, Vinod E.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (06) : E128 - E130
  • [22] EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy
    Shah, Manan P.
    Aredo, Jacqueline, V
    Padda, Sukhmani K.
    Ramchandran, Kavitha J.
    Wakelee, Heather A.
    Das, Millie S.
    Neal, Joel W.
    CLINICAL LUNG CANCER, 2022, 23 (02) : E148 - E153
  • [23] Resistance mechanisms to mobocertinib in treating NSCLC with EGFR exon 20 insertion mutations
    Le, Xiuning
    Nilsson, Monique
    Chatterjee, Sampurna
    Su, Zhenqiang
    He, Junqin
    Udagawa, Hibiki
    Yu, Xiaoxing
    Poteete, Alissa
    Huang, Qian
    Heymach, John V.
    Vincent, Sylvie
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [24] Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant
    Lihao Zhao
    Xiaona Cai
    Didi Chen
    Xuxue Ye
    Mengdan Gao
    Lihuai Lu
    Huafang Su
    Meng Su
    Meng Hou
    Congying Xie
    Radiation Oncology, 15
  • [25] Characterization of EGFR Exon 18 and 20 Mutations in NSCLC
    Farooqi, M.
    Oliver, D.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2014, 16 (06): : 757 - 757
  • [26] Poziotinib in NSCLC harbouring EGFR or HER2 exon 20 insertion mutation
    Prelaj, A.
    Bottiglieri, A.
    Galli, E.
    Lo Russo, G.
    Ferrara, R.
    Galli, G.
    De Toma, A.
    Brambilla, M.
    Occhipinti, M.
    Manglaviti, S.
    Beninato, T.
    Zattarin, E.
    Apollonio, G.
    Ganzinelli, M.
    Gallucci, R.
    Di Mauro, R. M.
    de Braud, F.
    Torri, V.
    Garassino, M. C. C.
    Proto, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S976 - S977
  • [27] Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
    Zhang, Shannon S.
    Zhu, Viola W.
    LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 61 - 65
  • [28] Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
    Lv, D.
    Lin, L.
    Wu, X.
    Yan, S.
    Ge, H.
    Yan, Z.
    Wang, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S634 - S634
  • [29] Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
    Lin, Ling
    Wu, Xiaomai
    Yan, Shuangquan
    Zhu, Yefei
    Yan, Zhengqing
    Lv, Dongqing
    Ge, Hongfei
    ONCOTARGETS AND THERAPY, 2020, 13 : 9753 - 9757
  • [30] Phase 3 Study of Pemetrexed-Platinum with or without Pembrolizumab for TKI-Resistant/EGFR-Mutated Advanced NSCLC: KEYNOTE-789
    Riely, G.
    Hui, R.
    Carbone, D.
    Park, K.
    Carrigan, M.
    Xu, X.
    Dang, T.
    Yang, J. Chih-Hsin
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S494 - S494
12345